GSK Will Fold Antibody Developer Domantis Into Biopharmaceutical CEDD
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK will pay $454 mil. to acquire Domantis’ technology for unconventional administration of monoclonal antibodies.